FrancophonIA/ELRC3.0 huggingface dataset:
English: Although the precise mechanism by which Fycompa works is not fully understood, it is thought to block the action of the neurotransmitter glutamate.
Estonian: Kuigi Fycompa täpne toimemehhanism ei ole täielikult teada, arvatakse, et aine blokeerib neurotransmitteri glutamaadi toime.
English: The main measure of effectiveness was the percentage of patients who experienced at least a 50% decrease in seizure frequency.
Estonian: Efektiivsuse põhinäitaja oli nende patsientide protsent, kellel vähenes epilepsiaepisoodide esinemissagedus vähemalt 50% võrra.
English: This is a summary of the European public assessment report (EPAR) for Fycompa.
Estonian: See on ravimi Fycompa Euroopa avaliku hindamisaruande kokkuvõte.
English: Glutamate is the main stimulatory neurotransmitter in nerve cells which can trigger and maintain seizures.
Estonian: Glutamaat on närvirakkudes põhiline stimuleeriv neurotransmitter, mis võib põhjustada episoodide vallandumist ja kestmist.
English: Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Fycompa have been included in the summary of product characteristics and the package leaflet.
Estonian: Fycompa ohutu ja efektiivse kasutamise soovitused ja ettevaatusmeetmed tervishoiutöötajatele ja patsientidele on lisatud ravimi omaduste kokkuvõttesse ja pakendi infolehele.
English: It is available as tablets (2, 4, 6, 8, 10 and 12 mg) and as an oral suspension (0.5 mg/ml, to be taken by mouth).
Estonian: Seda turustatakse tablettidena (2 mg, 4 mg, 6 mg, 8 mg, 10 mg ja 12 mg) ning suukaudse suspensioonina (0,5 mg/ml).
English: Neurotransmitters are naturally-occurring chemicals in the nervous system that allow nerve cells to communicate with each other.
Estonian: Neurotransmitterid on närvisüsteemi looduslikud keemilised ained, mis vahendavad närvirakkude vahelisi signaale.
English: For more information about treatment with Fycompa, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Estonian: Kui vajate Fycompaga toimuva ravi kohta lisateavet, lugege palun pakendi infolehte (mis on samuti Euroopa avaliku hindamisaruande osa) või pöörduge oma arsti või apteekri poole.
English: Supportive evidence from patients treated for up to 2 years suggested that the benefit was maintained with longer treatment and that some patients could benefit from doses up to 12 mg.
Estonian: Kuni 2 aasta jooksul ravitud patsientidelt saadud toetavad tõendid näitavad, et tulemus säilis pikemal raviperioodil ja mõnele patsiendile on kasulikud kuni 12 mg annused.
English: It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Fycompa.
Estonian: Selles selgitatakse, kuidas inimravimite komitee hindas ravimit ja otsustas toetada müügiloa andmist; samuti esitatakse komitee soovitused, kuidas ravimit kasutada.
English: In these studies, Fycompa was given at a dose of 2, 4, 8 or 12 mg per day for up to 19 weeks.
Estonian: Fycompat manustati neis uuringuis annuses 2, 4, 8 või 12 mg ööpäevas kuni 19 nädala jooksul.
English: The most common side effects with Fycompa (seen in more than 1 patient in 10) are dizziness and somnolence (sleepiness).
Estonian: Fycompa kõige sagedamad kõrvalnähud (esinenud enam kui 1 patsiendil 10st) on peapööritus ja unisus.
English: The CHMP considered that Fycompa, taken together with other anti-epileptic medicines, showed a consistent reduction in the frequency of epileptic fits and that no serious toxicity has been identified.
Estonian: Inimravimite komitee järeldas, et koos teiste epilepsiaravimitega manustatud Fycompa vähendas järjepidevalt epilepsiaepisoodide esinemissagedust ning rasket toksilisust ei tuvastatud.
English: For primary generalised tonic-clonic seizures Fycompa was shown to be effective in a study involving 164 patients with idiopathic generalised epilepsy.
Estonian: Primaarselt generaliseerunud toonilis-klooniliste epilepsiaepisoodide ravis tõendati Fycompa efektiivsust uuringus, milles osales 164 idiopaatilise generaliseerunud epilepsiaga patsienti.
English: The third study showed a significant decrease in seizure frequency only in patients taking 4 mg and 8 mg Fycompa but not in patients taking a dose of 2 mg.
Estonian: Kolmandas uuringus vähenes epilepsiaepisoodide esinemissagedus oluliselt üksnes patsientidel, kes võtsid Fycompat annuses 4 mg ja 8 mg, kuid mitte patsientidel, kes võtsid ravimit annuses 2 mg.
English: What is Fycompa?
Estonian: Mis on Fycompa?
English: Fycompa is a medicine that contains the active substance perampanel.
Estonian: Fycompa on ravim, mis sisaldab toimeainena perampaneeli.
English: Fycompa is also used in patients from 12 years of age to treat primary generalised tonic-clonic seizures (major fits or convulsions, where the person becomes unconscious, falls down if standing, and jerks or shakes) associated with idiopathic generalised epilepsy (epilepsy with no apparent cause that is thought to have a genetic origin and that affects the whole brain).
Estonian: Fycompaga ravitakse ka primaarselt generaliseerunud toonilis-kloonilisi epilepsiaepisoode (rasked epilepsiaepisoodid või konvulsioonid, millega kaasnevad teadvusekaotus ja püstiasendist kukkumine ning tõmblused ja värinad) vähemalt 12-aastastel patsientidel, kellel on idiopaatiline generaliseerunud epilepsia (epilepsia liik, mille tekkepõhjust peetakse geneetiliseks ja mis mõjutab kogu aju).
English: For the full list of all side effects and restrictions with Fycompa, see the package leaflet.
Estonian: Fycompa kõrvalnähtude ja piirangute täielik loetelu on pakendi infolehel.
English: Fycompa is used to treat adults and children from 12 years of age with partial-onset seizures (epileptic fits) with or without secondary generalisation.
Estonian: Fycompat kasutatakse täiskasvanute ja vähemalt 12-aastaste laste raviks, kellel on partsiaalsed epilepsiaepisoodid koos sekundaarse generaliseerumisega või ilma.
English: Treatment was started at a dose of 2 mg of Fycompa and gradually increased over 4 weeks to a maximum of 8 mg if tolerated, then continued for a further 13 weeks.
Estonian: Fycompa algannus oli 2 mg ja seda suurendati 4 nädala jooksul järk-järgult maksimumannuseni 8 mg (kui patsient seda talus); ravi jätkati veel 13 nädala jooksul.
English: Fycompa at doses from 4 mg to 12 mg was shown to be more effective than placebo in reducing the frequency of epileptic seizures.
Estonian: Annustes 4-12 mg manustatud Fycompa oli epilepsiaepisoodide esinemissageduse vähendamisel efektiivsem kui platseebo.
English: Why has Fycompa been approved?
Estonian: Miks Fycompa heaks kiideti?
English: In the management of partial onset seizures, Fycompa has been compared with placebo (a dummy treatment) in three main studies involving a total of 1,491 patients aged 12 years and older with partial-onset seizures who did not respond to other treatments.
Estonian: Partsiaalsete epilepsiaepisoodide ravis võrreldi Fycompat platseeboga (näiv ravim) kolmes põhiuuringus, kus osales kokku 1491 vähemalt 12-aastast patsienti, kellel olid partsiaalsed epilepsiaepisoodid ja kellel teiste ravimitega ei tekkinud ravivastust.
English: For patients with primary generalised tonic-clonic seizures Fycompa was also more effective than placebo: 47 of 81 patients (58%) given Fycompa had at least a 50% reduction in frequency of seizures, compared with 29 of 81 (36%) of those given the dummy treatment.
Estonian: Ka primaarselt generaliseerunud toonilis-klooniliste epilepsiaepisoodidega patsientidel osutus Fycompa efektiivsemaks kui platseebo: Patsiente, kelle epilepsiaepisoodide esinemissagedus vähenes vähemalt 50%, oli Fycompa uuringurühmas 58% (47 patsienti 81st) ja platseeborühmas 36% (29 patsienti
English: What is the risk associated with Fycompa?
Estonian: Mis riskid Fycompaga kaasnevad?
English: The active substance in Fycompa, perampanel, is an anti-epileptic medicine.
Estonian: Fycompa toimeaine perampaneel on epilepsiaravim.
English: In the first study, the percentage of patients who experienced a decrease in seizure frequency of at least 50% was 37.6% for patients taking 8 mg Fycompa and 36.1% for patients taking 12 mg Fycompa, compared with 26.4% of patients taking placebo.
Estonian: Esimeses uuringus oli patsiente, kellel vähenes epilepsiaepisoodide esinemissagedus vähemalt 50% võrra, 8 mg Fycompa manustamise korral 37,6% ja 12 mg korral 36,1%, platseebo korral 26,4%.
English: The recommended dose at the start of treatment is 2 mg per day, and if it is well tolerated the doctor may progressively increase it by increments of 2 mg/day to a maximum dose of 12 mg per day.
Estonian: Kui patsient talub ravimit hästi, tohib annust järk-järgult suurendada 2 mg võrra ööpäevas kuni maksimumannuseni 12 mg ööpäevas.
English: What benefit has Fycompa shown during the studies?
Estonian: Milles seisneb uuringute põhjal Fycompa kasulikkus?
English: Fycompa was compared with placebo as an addition to patients' existing epilepsy treatment.
Estonian: Fycompat võrreldi platseeboga teiste epilepsiaravimite lisaravimina.
English: Fycompa must only be used as an ‘add-on' therapy to other anti-epileptic medicines.
Estonian: Fycompat tohib kasutada üksnes teiste epilepsiaravimite lisaravimina.
English: How is Fycompa used?
Estonian: Kuidas Fycompat kasutatakse?
English: Therefore by blocking glutamate's actions, Fycompa is thought to stop epileptic seizures from occurring.
Estonian: Seega peatab Fycompa epilepsiaepisoodide esinemise arvatavasti sellega, et blokeerib glutamaadi toime.
English: How has Fycompa been studied?
Estonian: Kuidas Fycompat uuriti?
English: In the second study, 33.3% and 33.9% of patients taking 8 mg and 12 mg Fycompa respectively showed a decrease in seizure frequency of at least 50%, compared with 14.7% of patients taking placebo.
Estonian: Teises uuringus oli patsiente, kellel vähenes epilepsiaepisoodide esinemissagedus vähemalt 50% võrra, 8 mg Fycompa korral 33,3% ja 12 mg korral 33,9% ning platseebo korral 14,7%.
English: What is Fycompa used for?
Estonian: Milleks Fycompat kasutatakse?
English: How does Fycompa work?
Estonian: Kuidas Fycompa toimib?
English: Please note that:
Estonian: Palun pange tähele, et:
English: It is currently difficult to explain if this phenomenon is treatment related or not.
Estonian: Praegu on raske öelda, kas see nähtus on raviga seotud või mitte.
English: Tell your doctor:
Estonian: Rääkige sellest oma arstile:
English: If the vaccine has been frozen it should not be used.
Estonian: Kui vaktsiin on külmunud, ei tohi seda kasutada.
English: ◊Negative Pre-Vaccination titers were imputed to 5.
Estonian: ◊Negatiivsed vaktsineerimiseelsed tiitrid loeti olevat 5.
English: Many infected people develop mild symptoms or no symptoms at all.
Estonian: Paljudel nakatunud inimestel tekivad kerged sümptomid või ei teki neid üldse.
English: Safety and tolerability was evaluated in the entire study population.
Estonian: Ohutust ja taluvust hinnati kogu uuringupopulatsioonil.
English: In this case, your doctor will postpone the vaccination.
Estonian: Sellisel juhul lükkab arst vaktsineerimise edasi.
English: This vaccine has been prescribed for you and/or your child only.
Estonian: • See vaktsiin on välja kirjutatud üksnes teile ja/või teie lapsele.
English: Your doctor will discuss with you the possible risks and benefits of receiving IXIARO.
Estonian: Teie arst arutab teiega IXIARO manustamise võimalikke riske ja saadavat kasu.
English: Blank white foil without any printed information.
Estonian: Tühi valge foolium, millel puudub trükitud teave.
English: No prospective efficacy trials have been performed.
Estonian: Prospektiivseid tõhususe uuringuid ei ole tehtud.
English: In animal studies findings of unclear clinical relevance have been identified (see section 5.3).
Estonian: Loomkatsetes on leitud ebaselge kliinilise tähtsusega nähtusid (vt lõik 5.3).
English: The vaccine causes the body to produce its own protection (antibodies) against this disease.
Estonian: Vaktsiin paneb organismi ise tootma selle haiguse vastast kaitset (antikehi).
English: Long-term seroprotection following a booster-dose is not known.
Estonian: Pikaajaline seroprotektsioon pärast revaktsineerimisannust ei ole teada.
English: ATC code: J07BA02
Estonian: ATC-kood: J07BA02
English: This virus is mainly found in Asia and is transmitted to humans by mosquitoes that have bitten an infected animal (like pigs).
Estonian: Seda viirust esineb peamiselt Aasias ja see levib inimestele sääskede kaudu, kes on hammustanud nakatunud looma (näiteks sigu).
English: 1 dose (0.5 ml) of IXIARO contains:
Estonian: 1 annus (0,5 ml) IXIAROt sisaldab:
English: Day 35 Day 56 Day 365 NA= not applicable
Estonian: 35. päev 56. päev 365. päev NA= puudub
English: Tell your doctor if you and/or your child are taking or have recently taken, or might take any other medicines, including medicines obtained without a prescription or have recently received any other vaccine.
Estonian: Teatage oma arstile, kui teie ja/või teie laps kasutate või olete hiljuti kasutanud mingeid muid ravimeid, kaasa arvatud ilma retseptita ostetud ravimeid, või kui teile on hiljuti manustatud mõnda teist vaktsiini.
English: In patients receiving immunosuppressive therapy or patients with immunodeficiency an adequate immune response may not be obtained.
Estonian: Immunosupressiivset ravi kasutavatel patsientidel või immuunpuudulikkusega patsientidel ei pruugi küllaldane immuunvastus tekkida.
English: Adverse reactions are listed according to the following frequencies:
Estonian: Kõrvalnähud on esitatud järgmiste esinemissageduste järgi.
English: Approximately 40% of treated subjects experienced systemic adverse reactions and approximately 54% experienced injection site reactions.
Estonian: Ligikaudu 40%-l ravitud uuritavatest esines süsteemseid kõrvalnähte ja ligikaudu 54%-l reaktsioone süstekohal.
English: Date of first authorisation: 31 March 2009 Date of latest renewal: 22 November 2018
Estonian: Müügiloa esmase väljastamise kuupäev: 31. märts 2009 Müügiloa viimase uuendamise kuupäev: 28. veebruar 2014
English: As with many vaccines, the immune response in elderly persons to IXIARO is lower than in younger adults.
Estonian: Nagu paljude vaktsiinide korral, on eakate immuunvastus IXIARO-le väiksem kui noorematel täiskasvanutel.
English: Visit 0 (Screening) Visit 3 (Day 28) Visit 4 (Day 56)
Estonian: Visiit 0 (skriining) Visiit 3 (28. päev) Visiit 4 (56. päev)
English: No symptoms related to overdose were reported.
Estonian: Üleannustamisega seotud sümptomitest ei ole teatatud.
English: If a needle is not provided, use a sterile needle.
Estonian: Kui nõela ei ole kaasas, kasutage steriilset nõela.
English: The pre-filled syringe is for single use only and should not be used for more than one person.
Estonian: Süstel on ette nähtud ainult ühekordseks kasutamiseks ja seda ei tohi kasutada mitmel inimesel.
English: C. OTHER CONDITIONS OR REQUIREMENTS OF THE MARKETING AUTHORISATION • Periodic Safety Update Reports
Estonian: C. MÜÜGILOA MUUD TINGIMUSED JA NÕUDED • Perioodilised ohutusaruanded
English: Email: infoixiaro@valneva.com
Estonian: E-post: infoixiaro@valneva.com
English: Read all of this leaflet carefully before you or your child receive this vaccine because it contains important information for you.
Estonian: Lugege hoolikalt infolehte, enne kui seda vaktsiini teile või teie lapsele manustatakse, sest siin on teile vajalikku teavet.
English: The printed package leaflet of the medicinal product must state the name and address of the manufacturer responsible for the release of the concerned batch.
Estonian: Ravimi trükitud pakendi infolehel peab olema vastava ravimipartii kasutamiseks vabastamise eest vastutava tootja nimi ja aadress.>
English: 95% Confidence Interval
Estonian: 95% usaldusvahemik
English: Do not use this medicine after the expiry date which is stated on the carton and label after “EXP”.
Estonian: • Ärge kasutage seda ravimit pärast kõlblikkusaega, mis on märgitud karbil ja sildil pärast „Kõlblik kuni“ ja „EXP“.
English: Seroconversion rates and antibody titers also remained comparably high up to 12 months after the first immunisation in both schedules (Table 5).
Estonian: Ka serokonversiooni määrad ja antikehade tiitrid jäid võrreldavalt kõrgeks kuni 12 kuud pärast esimest immuniseerimist mõlema skeemi alusel (tabel 5).
English: If not, you and/or your child may not be fully protected against the disease.
Estonian: Vastasel juhul ei pruugi teie ja/või teie laps olla haiguse vastu täielikult kaitstud.
English: All of the 198 subjects treated were included in the ITT and Safety Populations.
Estonian: Kõik 198 ravitud uuringus osalejat kuulusid ravieesmärgiga ja ohutusuuringu populatsioonidesse.
English: Non-clinical toxicity data are limited.
Estonian: Mittekliinilised toksilisuse andmed on piiratud.
English: The observed decline in GMT is as expected and compares well with data from other inactivated JE vaccines.
Estonian: GMT väärtuses täheldatud langus on eeldatav ja võrreldav teiste JE inaktiveeritud vaktsiinide korral saadud andmetega.
English: Other medicines and IXIARO
Estonian: Muud ravimid ja IXIARO
English: Day 0 Day 14
Estonian: Päev 0 14. päev
English: Immunogenicity and safety in children and adolescents from non-endemic countries
Estonian: Immunogeensus ja ohutus lastel ja noorukitel endeemiata riikides
English: Signs of an allergic reaction may include an itchy rash, shortness of breath and swelling of the face and tongue.
Estonian: Allergilise reaktsiooni tunnuste hulka võivad kuuluda sügelev lööve, õhupuudus ning näo ja keele turse.
English: If the primary immunization of two injections is not completed, full protection against the disease might not be achieved.
Estonian: Kui esmane kaheannuseline vaktsineerimine jääb lõpule viimata, ei pruugi see anda haiguse vastu täielikku kaitset.
English: Booster dose 12 months after primary immunization N = 149
Estonian: Revaktsineerimisannus 12 kuud pärast esmast vaktsineerimist N = 149
English: This product might contain traces of residual sodium metabisulfite which is below detection limit.
Estonian: Preparaat võib sisaldada naatriummetabisulfiti jääkide jälgi, mis jäävad allapoole avastamispiiri.
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor for advice before receiving this vaccine.
Estonian: Kui te olete rase, imetate või arvate end olevat rase või kavatsete rasestuda, pidage enne selle vaktsiini saamist nõu oma arstiga.
English: However, it should be noted that there are no clinical efficacy data to support administration by the subcutaneous route.
Estonian: Tuleb siiski märkida, et kliinilised tõhususe andmed nahaaluse manustamise toetuseks puuduvad.
English: Contents of the pack and other information What IXIARO contains
Estonian: Pakendi sisu ja muu teave Mida IXIARO sisaldab
English: You can also report side effects directly via the national reporting system listed in Appendix V.
Estonian: Kõrvaltoimetest võite ka ise teavitada riikliku teavitamissüsteemi, mis on loetletud V lisas, kaudu.
English: IXIARO is a white and slightly milky sterile suspension, which becomes homogenous on shaking.
Estonian: IXIARO on valge ja kergelt piimjas steriilne suspensioon, mis muutub loksutamisel ühtlaseks.
English: These studies showed that almost all mice that had a Plaque Reduction Neutralization Test titre of at least 1:10 were protected from a lethal Japanese encephalitis virus challenge.
Estonian: Need uuringud näitasid, et peaaegu kõik hiired, kelle naastu reduktsiooni neutralisatsioonitesti tiiter oli vähemalt 1:10, olid kaitstud Jaapani entsefaliidi viiruse surmava ekspositsiooni eest.
English: The safety and efficacy of IXIARO in children younger than 2 months has not been established.
Estonian: IXIARO ohutus ja efektiivsus ei ole alla 2 kuu vanustel lastel tõestatud.
English: Your doctor will decide on the requirement and timing for booster doses.
Estonian: Teie arst otsustab revaktsineerimisannuste vajaduse ja ajastuse üle.
English: For elderly persons (>65 years) the first booster dose may be given earlier.
Estonian: Eakatele (> 65 eluaastat) võib manustada esimese revaktsineerimisannuse varem.
English: Pre-booster, Day 0 (n=198) Day 28 (n=198) Month 6 (n=197) Month 12 (n=194)
Estonian: Enne revaktsineerimist, 0 päev (n = 198) 28. päev (n = 198) 6 kuud (n = 197) 12 kuud (n = 194)
English: As with all injectable vaccines, appropriate medical treatment and supervision should always be available to treat rare cases of anaphylactic reactions following the administration of the vaccine.
Estonian: Nagu kõigi süstitavate vaktsiinide kasutamisel, peavad asjakohane ravi ja jälgimine selle vaktsiini manustamise järel harvaesinevate anafülaktiliste reaktsioonide korral olema alati kättesaadavad.
English: Confusion and agitation also occur in the early stage of disease.
Estonian: Haiguse varases staadiumis tekib ka segasusseisund ja rahutus.
English: In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
Estonian: Bioloogiliste ravipreparaatide jälgitavuse parandamiseks tuleb selgelt dokumenteerida manustatava preparaadi nimi ja partiinumber.
English: If you and/or your child are ill with a high fever.
Estonian: • kui teil ja/või teie lapsel on palavikuga haigus.
English: IXIARO cannot cause the disease it protects against.
Estonian: • IXIARO ei saa põhjustada haigust, mille vastu ta kaitseb;
English: Aluminium hydroxide is included in this vaccine as an adjuvant.
Estonian: Alumiiniumhüdroksiid toimib vaktsiinis adjuvandina.
English: Protection against Japanese Encephalitis is not ensured until the second dose has been received.
Estonian: Jaapani entsefaliidi vastane kaitse on tagatud alles pärast teise annuse saamist.
English: 3 years
Estonian: <3 aastat
English: Studies in animals have shown that the vaccine triggers the immune system to produce antibodies against Japanese encephalitis virus that are most often protective.
Estonian: Uuringud loomadel on näidanud, et vaktsiin paneb immuunsüsteemi Jaapani entsefaliidiviiruse vastu tootma peamiselt kaitsvaid antikehi.
English: The booster dose led to a pronounced increase in GMTs and seroprotection rate remained at 100% two years after the booster.
Estonian: Revaktsineerimisannus põhjustas GMT märgatavat suurenemist ja seroprotektsiooni määr püsis 100% kaks aastat pärast revaktsineerimist.
English: The safety profile of IXIARO was comparable to that of Havrix or Prevenar.
Estonian: IXIARO ohutusprofiil oli võrreldav Havrixi või Prevenari omaga.
English: n.a. 95% Confidence Interval could not be established (single-subject data)
Estonian: 136 [n.a.] n.a. 95% usaldusvahemikku ei olnud võimalik leida (ühe uuringus osaleja andmed)
English: There was also no interference with the immune response to Rabipur.
Estonian: Samuti puudusid häired Rabipurile tekkinud immuunvastuse osas.
English: If you forget to get IXIARO
Estonian: Kui te unustate IXIAROt saada
English: Very common: ≥ 1/10
Estonian: Väga sage: ≥ 1/10
English: Valneva Scotland Ltd. Oakbank Park Road Livingston EH53 0TG United Kingdom
Estonian: Valneva Scotland Ltd. Oakbank Park Road, Livingston EH53 0TG Ühendkuningriik
English: Ask your pharmacist how to throw away medicines you and/or your child no longer use.
Estonian: Küsige oma apteekrilt, kuidas visata ära ravimeid, mida te enam ei kasuta.
English: If you and/or your child have any other known allergies.
Estonian: • kui teil ja/või teie lapsel on mõni muu teadaolev allergia;
English: corresponding to a potency of ≤ 460 ng ED50
Estonian: mis vastab ≤ 460 ng ED50 tugevusele.
English: Day 21
Estonian: 21. päev
English: You should take appropriate precautions for you and your child to reduce mosquito bites (adequate clothing, use of repellents, mosquito nets) even after receiving IXIARO.
Estonian: • sääsehammustuste vähendamiseks tuleb teil ja teie lapsel asjakohaseid ettevaatusabinõusid (sobiv riietus, putukatõrjevahendite kasutamine, sääsevõrgud) kasutada ka pärast IXIARO manustamist.